Impact of Steroids on Inflammatory Response in Covid-19

The Impact of Dexamethasone Versus Methylprednisolone Upon Neutrophil/Lymphocyte Ratio (NLR) in COVID-19 Diseased Patients Admitted in ICU

we designed this study to observe the efficacy and safety of dexamethasone versus methylprednisolone in covid-19 diseased patients upon monitoring the inflammatory response and to compare the outcome when these steroids will be given in covid-19 diseased patients in our ICU.

A written informed consent will be taken from the patients or their relatives. The study will involve adults (age 18-no limit years) who will be diagnosed covid-19 with destructive inflammatory immune response needing ICU admission to be run on steroid therapy.

Patients will be assigned randomly to two groups (30 subjects each). The study drug will be delivered in opaque bags labeled "study drug" and in (Group D) intravenous dexamethasone 8 mg/day given for 7 days, in (Group M) intravenous methylprednisolone 1 mg/kg/day in 2 divided doses per day given for 7 days.

Inclusion Criteria:

• Adults (age 18-no limit years) who will be diagnosed covid-19
• With destructive inflammatory immune response needing ICU admission to be run on steroid therapy.

Exclusion Criteria:

• Severe immunosuppression like HIV (Human immunodeficiency Virus)
• Long term use of immunosuppressant for any other chronic illness
• Pregnant or lactating females
• Patients who are on chronic use of corticosteroids like asthma, rheumatoid arthritis.